# US 2025/0152536 A1 · Delivery of an antioxidant compound for treating seizures, viral infections, exposure to chemical warfare agents, and other conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152536 A1
- Document ID: US20250152536A1
- Status: Published application
- Kind: A1
- Application number: 18/838,178
- Filed: 2023-02-16
- Published: 2025-05-15
- Earliest claimed: 2022-02-16
- Applicants: Beyond Barriers Therapeutics, Inc.
- Inventors: Ryan Kole; Brian Reinhardt; Jeffery Lewine
- Web page: https://patentgrep.com/patent/US20250152536A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/0043: {Nose}
- A61K 38/063: {Glutathione}
- A61K 38/446: {Superoxide dismutase (1.15)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Methods, formulations, and kits comprising an antioxidant compound for treatment of seizures, viral infections, encephalitis, exposure to chemical warfare agents, and/or exposure to a pesticide. An antioxidant such as N-acetyl cysteine (NAC) or a pharmaceutically acceptable salt is delivered by administration to a subject in need of treatment. Methods, formulations and kits may also comprise a cholinergic muscarinic antagonist, a cholinesterase reactivator, or both, and/or an inhibitor of a purinergic receptor, and/or a benzodiazepam. Kits for treating the subject comprising (a) at least one antioxidant compound or a pharmaceutically acceptable salt thereof, (b) an intranasal delivery device, and (c) an intramuscular delivery device. The pharmaceutical formulations can be pre-formulated into vials or cartridges that can be loaded into the intranasal delivery device or intramuscular delivery device.

## Claims

### Claim 1

A method of treating a seizure, viral infection, encephalitis, exposure to a chemical warfare agent, and/or exposure to a pesticide, wherein the method comprises:
intranasally administering to a subject in need of treatment for a seizure, viral infection, encephalitis, exposure to a chemical warfare agent, and/or exposure to a pesticide, an effective amount of at least one antioxidant compound or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for a seizure.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for a viral infection.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for exposure to a chemical warfare agent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for exposure to a pesticide.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject is in need of treatment for exposure to an organophosphate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for encephalitis, such as encephalitis caused by viral infection, exposure to a chemical warfare agent, and/or exposure to a pesticide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antioxidant compound is selected from the group consisting of N-acetylcysteine (NAC), glutathione, co-enzyme Q-10, superoxide dismutase (SOD), and a combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antioxidant compound is N-acetylcysteine (NAC) or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1, 9)

The method of claim 1 or claim 9, wherein the method further comprises administering to the subject an inhibitor of a purinergic receptor selected from the group consisting of P2X4, P2X7, P2Y6, and P2Y12.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method further comprises administering to the subject a cholinergic muscarinic antagonist, a cholinesterase reactivator, or both.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cholinergic muscarinic antagonist is atropine, ipratropium, or a pharmaceutically acceptable salt thereof; and the cholinesterase reactivator is pralidoxime chloride (2-PAM Cl) or other oxime.

### Claim 13 (depends on 10)

The method of claim 10, further comprising administering a benzodiazepam to the subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for infection with a neurotropic virus.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is in need of treatment for infection with an alphavirus.

### Claim 16 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the virus is a naturally occurring virus.

### Claim 17 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the virus is a genetically modified virus or a weaponized virus.

### Claim 18 (depends on 1)

The method of claim 1, wherein the at least one antioxidant is administered in combination with a chitosan loaded nanoparticle, a lipophilic micelle, or a liposomal carrier.

### Claim at position 19

-86. (canceled)

### Claim 87 (depends on 1)

The method of claim 1, wherein the at least one antioxidant is administered in combination with one or more of adipic acid, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, dithiothreitol, glutamic acid, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium sulfite, sodium thiosulfate, tartaric acid, thioglycerol, throurea, tocopherols, p-toluene sulfonic acid, EDTA, fumaric acid or malic acid.

### Claim 88 (depends on 1)

The method of claim 1, wherein the at least one antioxidant is administered in combination with 1-O-n-Dodecyl-β-D_Maltopyranoside (DDM).
